The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis

Background: Studies have shown that circulating tumor DNA (ctDNA) indicates a poor prognosis in ovarian cancer. In this study, meta-analysis was used to assess the relationship between ctDNA and the prognosis of patients with epithelial ovarian cancer. Methods: The clinical trials included in this s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yuanyuan Lu MD, Li Li PhD
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/5ae911caed4e42268e093c0f11bd3136
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5ae911caed4e42268e093c0f11bd3136
record_format	dspace
spelling	oai:doaj.org-article:5ae911caed4e42268e093c0f11bd31362021-12-02T01:03:54ZThe Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis1533-033810.1177/15330338211043784https://doaj.org/article/5ae911caed4e42268e093c0f11bd31362021-11-01T00:00:00Zhttps://doi.org/10.1177/15330338211043784https://doaj.org/toc/1533-0338Background: Studies have shown that circulating tumor DNA (ctDNA) indicates a poor prognosis in ovarian cancer. In this study, meta-analysis was used to assess the relationship between ctDNA and the prognosis of patients with epithelial ovarian cancer. Methods: The clinical trials included in this study were obtained via a search of PubMed, the Cochrane Library, the Web of Science and Embase between the period of establishment and March 2020. We selected clinical studies using qualitative or quantitative ctDNA methods to analyse the prognosis of ovarian epithelial cancer, screened the studies according to the determined inclusion and exclusion criteria, and used the modified JADAD score scale and NOS scale for evaluation, with OS (overall survival) and PFS (progression-free survival) as end events. The Cochrane Evaluation Tool was used to evaluate the quality of the randomized controlled trials. Stata 15.0 software was used to combine the effect ratio (hazard ratio, HR) and its 95% confidence interval (CI). In addition, a source analysis of ctDNA specimens, an analysis of ctDNA detection methods and a subgroup and sensitivity analysis of FIGO staging were performed. Results: A total of 8 studies were included in this meta-analysis, and ctDNA was found to be an independent risk factor for patients with epithelial ovarian cancer (OS: HR = 2.36, 95% CI [1.76,3.17], P < .001; PFS: HR = 2.51, 95% CI [1.83,3.45]). Conclusions: The results of our analysis suggested that ctDNA is a potential biomarker that can be used to evaluate the prognosis of patients with ovarian cancer.Yuanyuan Lu MDLi Li PhDSAGE PublishingarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENTechnology in Cancer Research & Treatment, Vol 20 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yuanyuan Lu MD Li Li PhD The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis
description	Background: Studies have shown that circulating tumor DNA (ctDNA) indicates a poor prognosis in ovarian cancer. In this study, meta-analysis was used to assess the relationship between ctDNA and the prognosis of patients with epithelial ovarian cancer. Methods: The clinical trials included in this study were obtained via a search of PubMed, the Cochrane Library, the Web of Science and Embase between the period of establishment and March 2020. We selected clinical studies using qualitative or quantitative ctDNA methods to analyse the prognosis of ovarian epithelial cancer, screened the studies according to the determined inclusion and exclusion criteria, and used the modified JADAD score scale and NOS scale for evaluation, with OS (overall survival) and PFS (progression-free survival) as end events. The Cochrane Evaluation Tool was used to evaluate the quality of the randomized controlled trials. Stata 15.0 software was used to combine the effect ratio (hazard ratio, HR) and its 95% confidence interval (CI). In addition, a source analysis of ctDNA specimens, an analysis of ctDNA detection methods and a subgroup and sensitivity analysis of FIGO staging were performed. Results: A total of 8 studies were included in this meta-analysis, and ctDNA was found to be an independent risk factor for patients with epithelial ovarian cancer (OS: HR = 2.36, 95% CI [1.76,3.17], P < .001; PFS: HR = 2.51, 95% CI [1.83,3.45]). Conclusions: The results of our analysis suggested that ctDNA is a potential biomarker that can be used to evaluate the prognosis of patients with ovarian cancer.
format	article
author	Yuanyuan Lu MD Li Li PhD
author_facet	Yuanyuan Lu MD Li Li PhD
author_sort	Yuanyuan Lu MD
title	The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis
title_short	The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis
title_full	The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis
title_fullStr	The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis
title_full_unstemmed	The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis
title_sort	prognostic value of circulating tumor dna in ovarian cancer: a meta-analysis
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/5ae911caed4e42268e093c0f11bd3136
work_keys_str_mv	AT yuanyuanlumd theprognosticvalueofcirculatingtumordnainovariancancerametaanalysis AT liliphd theprognosticvalueofcirculatingtumordnainovariancancerametaanalysis AT yuanyuanlumd prognosticvalueofcirculatingtumordnainovariancancerametaanalysis AT liliphd prognosticvalueofcirculatingtumordnainovariancancerametaanalysis
_version_	1718403317850177536

The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis

Ejemplares similares